What is Genprex?
Genprex, Inc. is dedicated to pioneering life-changing gene therapies for patients battling cancer and diabetes. The company's innovative technologies are engineered to deliver disease-fighting genes, aiming to provide new therapeutic avenues for extensive patient populations who currently face limited treatment alternatives. Genprex collaborates with leading institutions and partners to advance its pipeline of gene therapies, striving to introduce novel treatments to the market.
How much funding has Genprex raised?
Genprex has raised a total of $33M across 2 funding rounds:
Stock Offering
$25.5M
Share Placement
$7.5M
Stock Issuance/Offering (2020): $25.5M, investors not publicly disclosed
Share Placement (2023): $7.5M, investors not publicly disclosed
What's next for Genprex?
The recent major strategic investment signals a pivotal phase for Genprex, likely enabling the acceleration of its clinical trials and the expansion of its research and development initiatives. This infusion of capital is expected to bolster the company's efforts in bringing its promising gene therapies from the laboratory to patients in need. The company's focus on addressing significant unmet medical needs in oncology and endocrinology positions it for potential breakthroughs and future growth within the competitive biotechnology landscape.
See full Genprex company page
